Denali Therapeutics Statistics
Total Valuation
DNLI has a market cap or net worth of $3.41 billion. The enterprise value is $2.72 billion.
Important Dates
The next estimated earnings date is Thursday, February 26, 2026, after market close.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DNLI has 156.16 million shares outstanding. The number of shares has increased by 9.46% in one year.
| Current Share Class | 156.16M |
| Shares Outstanding | 156.16M |
| Shares Change (YoY) | +9.46% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 4.53% |
| Owned by Institutions (%) | 91.92% |
| Float | 141.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 313.09 |
| PB Ratio | 3.60 |
| P/TBV Ratio | 3.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.79, with a Debt / Equity ratio of 0.05.
| Current Ratio | 9.79 |
| Quick Ratio | 9.43 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -782.60 |
Financial Efficiency
Return on equity (ROE) is -44.44% and return on invested capital (ROIC) is -366.99%.
| Return on Equity (ROE) | -44.44% |
| Return on Assets (ROA) | -27.29% |
| Return on Invested Capital (ROIC) | -366.99% |
| Return on Capital Employed (ROCE) | -56.74% |
| Weighted Average Cost of Capital (WACC) | 9.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$964,689 |
| Employee Count | 517 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DNLI has paid $68,000 in taxes.
| Income Tax | 68,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.33% in the last 52 weeks. The beta is 1.05, so DNLI's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | -8.33% |
| 50-Day Moving Average | 18.42 |
| 200-Day Moving Average | 15.71 |
| Relative Strength Index (RSI) | 61.71 |
| Average Volume (20 Days) | 1,750,858 |
Short Selling Information
The latest short interest is 14.86 million, so 9.52% of the outstanding shares have been sold short.
| Short Interest | 14.86M |
| Short Previous Month | 14.56M |
| Short % of Shares Out | 9.52% |
| Short % of Float | 10.47% |
| Short Ratio (days to cover) | 10.76 |
Income Statement
| Revenue | n/a |
| Gross Profit | -420.66M |
| Operating Income | -547.82M |
| Pretax Income | -498.68M |
| Net Income | -498.74M |
| EBITDA | -542.07M |
| EBIT | -547.82M |
| Earnings Per Share (EPS) | -$2.91 |
Full Income StatementBalance Sheet
The company has $848.20 million in cash and $44.48 million in debt, with a net cash position of $828.43 million or $5.31 per share.
| Cash & Cash Equivalents | 848.20M |
| Total Debt | 44.48M |
| Net Cash | 828.43M |
| Net Cash Per Share | $5.31 |
| Equity (Book Value) | 926.20M |
| Book Value Per Share | 6.32 |
| Working Capital | 792.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$397.78 million and capital expenditures -$13.07 million, giving a free cash flow of -$410.85 million.
| Operating Cash Flow | -397.78M |
| Capital Expenditures | -13.07M |
| Free Cash Flow | -410.85M |
| FCF Per Share | -$2.63 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DNLI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.46% |
| Shareholder Yield | -9.46% |
| Earnings Yield | -14.05% |
| FCF Yield | -11.57% |
Analyst Forecast
The average price target for DNLI is $31.58, which is 44.80% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $31.58 |
| Price Target Difference | 44.80% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
